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Abstract Leukemia inhibitory factor (LIF) has been shown
to protect oligodendrocytes from ischemia by upregulating
endogenous antioxidants. The goal of this study was to deter-
mine whether LIF protects neurons during stroke by upregu-
lating superoxide dismutase 3 (SOD3). Animals were admin-
istered phosphate-buffered saline (PBS) or 125 μg/kg LIF at
6, 24, and 48 h after middle cerebral artery occlusion or sham
surgery. Neurons were isolated from rat pups on embryonic
day 18 and used between 7 and 15 days in culture. Cells were
treated with LIF and/or 10 μMAkt inhibitor IV with PBS and
0.1 % DMSO acting as vehicle controls. Neurons transfected
with scrambled or SOD3 small interfering RNA (siRNA)
were subjected to 24-h ischemia after PBS or LIF treatment.
LIF significantly increased superoxide dismutase activity and
SOD3 expression in ipsilateral brain tissue compared to PBS.
Following 24-h ischemia, LIF reduced cell death and in-
creased SOD3 messenger RNA (mRNA) in vitro compared
to PBS. Adding Akt inhibitor IV with LIF counteracted the
decrease in cell death. Partially silencing the expression of
SOD3 using siRNA prior to LIF treatment counteracted the
protective effect of LIF-alone PBS treatment. These results
indicate that LIF protects neurons in vivo and in vitro via
upregulation of SOD3.
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Abbreviations




FCI Focal cerebral ischemia
gp130 Glycoprotein 130
HUCB Human umbilical cord blood
LDH Lactate dehydrogenase
LIF Leukemia inhibitory factor
LIFR LIF receptor
MAP2 Microtubule-associated protein 2
MCAO Middle cerebral artery occlusion
NO Nitric oxide
NADPH Nicotinamide adenine dinucleotide phosphate
OGD Oxygen glucose deprivation
Prdx4 Peroxiredoxin IV
qRT-PCR Quantitative reverse-transcriptase PCR
ROS Reactive oxygen species
SOD Superoxide dismutase
Introduction
Reactive oxygen species (ROS) play an instrumental role in
both the acute and delayed phases of neuronal death during
focal cerebral ischemia (FCI). During the early phase of ische-
mia, energy failure leads to membrane depolarization [1], cal-
cium influx, and activation of pro-oxidant enzymes such as
neuronal nitric oxide (NO) synthase [2] and nicotinamide ad-
enine dinucleotide phosphate (NADPH) oxidase [3]. These
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enzymes generate ROS, such as peroxynitrite and superoxide,
which damage cellular components and trigger neuronal death
[4]. A second wave of neuronal death occurs during the period
of delayed neuroinflammation, which may continue hours to
days after the initial injury [5]. The activation of microglia
exacerbates oxidative damage to neurons via inducible NO
synthase activation [6]. Furthermore, matrix metalloprotein-
ases derived from activated microglia compromise blood–
brain barrier (BBB) function by disrupting tight junctions
[7–9]. Increased BBB permeability allows for the invasion
of peripheral lymphocytes, monocytes/macrophages, and neu-
trophils [10]. The accumulation of immune cells in the brain
damages already degenerating neurons in the penumbra [11].
Since the therapeutic window for tissue plasminogen activa-
tor, the only FDA-approved drug for ischemic stroke, ranges
from 3 to 4.5 h after stroke, it cannot target this delayed phase
of neuronal death [12]. Consequently, the need for novel
stroke therapeutics that will protect vulnerable neurons from
oxidative stress remains high.
While small molecule scavengers of ROS have demon-
strated limited efficacy in clinical trials [13], overexpressing
endogenous antioxidant enzymes may be more effective than
administering exogenous agents. These enzymes include
those in the superoxide dismutase (SOD) family, which react
with excess superoxide to form hydrogen peroxide and water.
Three SOD isoforms have been identified in mammals [14,
15]. Moreover, a decreased activity of SOD enzymes yields
deleterious effects on nervous system function. The G93A
mutation in SOD1, a ubiquitously expressed cytoplasmic en-
zyme, is associated with familial amyotrophic lateral sclerosis
(ALS) [16–18]. Dysfunction of SOD2, which regulates ROS
production in the mitochondria [19], is implicated in the de-
velopment of conditions such as Alzheimer’s disease [20–22]
and Parkinson’s disease [22]. Superoxide dismutase 3
(SOD3), the extracellular isoform with the lowest expression
in neural cells [23], opposes the negative effects of hyperten-
sion in the brain by increasing NO bioavailability and regulat-
ing cerebral blood flow [24].
Several murine studies have implicated the neuroprotective
role of SOD enzymes following FCI. Delivery of the SOD1
gene via herpes simplex virus protects mice against cerebral
ischemia/reperfusion injury [25]. SOD2 homozygous knock-
out mice had greater infarct volumes after transient FCI com-
pared to their wild-type counterparts [26]. Conversely, mice
overexpressing SOD3 showed resistance to neural cell dam-
age following transient FCI [27]. Nonetheless, information
regarding the role of SOD3 in protecting neurons remains
limited.
Few studies focus on exogenous agents that upregulate the
expression of these enzymes. Previous data from this lab dem-
onstrates the therapeutic potential of upregulating endogenous
antioxidant enzymes as a protective strategy against stroke.
Specifically, the Akt-dependent upregulation of the
antioxidant enzyme peroxiredoxin IV (Prdx4) contributes to
human umbilical cord blood (HUCB) cell-mediated protec-
tion of oligodendrocytes [28, 29]. This lab has chosen to focus
on released factors such as leukemia inhibitory factor (LIF),
which provide neural cell protection while avoiding cellular
treatment [28, 30].
LIF, an anti-inflammatory cytokine in the interleukin-6
family [31], binds to a heterodimeric receptor consisting of
the LIF receptor (LIFR) and glycoprotein 130 (gp130) sub-
units. Upon binding, several downstream signaling pathways
are activated including the MAPK [32], PI3K/Akt [33], and
JAK/STAT pathway [34, 35]. These signaling cascades, espe-
cially the PI3K/Akt pathway, play an instrumental role in the
pro-survival and neurotrophic effects of LIF [36].
LIF has shown promising results as a therapeutic in several
animal models of neurodegenerative disease. The administra-
tion of LIF reduces demyelination in the experimental auto-
immune encephalomyelitis model of multiple sclerosis [37]
and a murine model of spinal cord injury [38]. In addition,
LIF reduced degeneration of motor neurons in the SOD1
G93A murine model of familial ALS [39]. Recently, we
showed that LIF decreases infarct volume, improves function-
al recovery, and upregulates Prdx4 in oligodendrocytes after
ischemia [40]. Although LIF is released by several cell types
during brain injury [41–43], its potential as a stroke therapeu-
tic has not yet been determined.
The ability of LIF to activate protective pathways and re-
duce neural cell damage in several animal models of disease
makes it a prime candidate for targeting delayed neuronal
death after stroke. The goal of this study is to identify the
molecular mechanisms by which LIF exerts neuroprotection
after permanent FCI. This lab tested the hypothesis that LIF
increases neuronal survival after stroke by upregulating SOD
enzyme expression and activity.
Materials and Methods
Animal Care
All animal procedures were conducted in agreement with the
NIH Guide for the Care and Use of Laboratory Animals.
Experimental protocols were approved by the Institutional
Animal Care and Use Committee at the University of South
Florida. Power analysis was conducted prior to experiments to
determine the minimum number of animals required to detect
significant effects. Sprague–Dawley rats were purchased from
Harlan Labs (Indianapolis, IN, USA), maintained on a 12-h
light–dark cycle (07:00–19:00 hours) in a climate-controlled
room, and allowed access to food and water ad libitum.
Neurons for in vitro experiments were taken from embryonic
day 18 (E18) rat pups obtained from timed pregnant dams.
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Young, male rats weighing 300 to 350 g were used for in vivo
experiments.
Permanent Middle Cerebral Artery Occlusion
and Administration of LIF
Induction of FCI was achieved using the permanent middle
cerebral artery occlusion (MCAO) model as previously de-
scribed [44]. Briefly, an incision was made near the sternum
and blunt dissection was used to expose the common carotid
artery. After ligating and cutting the external carotid artery, a
40-mm monofilament was introduced and fed through the
internal carotid artery. The monofilament was advanced to
the base of the middle cerebral artery. The monofilament
was secured and the wound was closed using polypropylene
sutures. Laser Doppler (Moore Lab Instruments, Farmington,
CT) was used to confirm the reduction in cerebral blood flow.
Animals experiencing less than a 60% reduction in CBF were
excluded from analysis. For the sham MCAO procedure, the
common carotid artery was exposed without subsequent oc-
clusion of the middle cerebral artery. Animals were adminis-
tered recombinant human LIF (ProSpec, Ness Ziona, Israel)
(125 μg/kg) intravenously at 6, 24, and 48 h post-MCAO.
Phosphate-buffered saline (PBS) pH 7.4 was used as a vehicle
control for the LIF. Rats were euthanized 24, 48, and 72 h
post-MCAO for immunohistochemistry or biochemical anal-
ysis. The number of subjects in each treatment group was as
follows 24 h PBS: n=3; 24 h LIF: n=5; 48 h PBS: n=4; 48 h
LIF: n=4; 72 h PBS: n=12; and 72 h LIF: n=10.
Histochemical Analysis
Tissue sections were prepared for histochemical analysis as
previously described [45]. Following euthanization, animals
were perfused transcardially with normal saline followed by
4 % paraformaldehyde in PBS (pH 7.4). Brains were removed
and incubated in 4 % paraformaldehyde followed by 20 and
30 % sucrose solutions. Brains were cut into 30-μm sections
including the bregma −1.7 mm through +3.3 mm. 3,3-
Diaminobenzidine (DAB) immunohistochemistry was per-
formed as previously described [46]. This procedure was also
performed as previously described [28] on 18-mm glass cov-
erslips containing primary cortical rat neurons. The following
antibodies were used for immunological detection: mouse α-
SOD3 (1:250; Novus Biologicals, Littleton, CO), rabbit α-
phospho-Akt (Ser473) (1:50; Cell Signaling, Danvers, MA)
[29], and rabbit α-active caspase-3 (1:1000; Sigma-Aldrich,
St. Louis, MO) [29]. Biotinylated secondary antibodies
(1:300; Vector Laboratories, Burlingame, CA) were used in
conjunction with their complimentary primary counterparts.
Fluorescent immunohistochemistry was performed on
brain tissue sections as previously described [28] using rabbit
α-microtubule-associated protein 2 (MAP2) (1:200; EMD
Millipore, Billerica, MA) and mouse α-SOD3 (1:250;
Novus Biologicals) [47] antibodies. Tissue sections were also
double-labeled with mouse α-SOD3 (1:250; Novus
Biologicals) and rabbit anti-phospho-Akt (Ser473) (1:50;
Cell Signaling) or rabbit-α-LIFR (1:200; Santa Cruz
Biotechnology, Dallas, TX) [37] and rabbit α-MAP2 (1:200;
EMD Millipore) [48] antibodies. AlexaFluor® 488 and 594
secondary antibodies (1:1000; Life Technologies, Carlsbad,
CA) were used for fluorescent visualization and slides were
mounted using VECTASHIELD® medium containing 4′,6-
diamidino-2-phenylindole (DAPI) (Vector Labs). Images
were captured using a Zeiss AxioCam color camera attached
to a Zeiss AxioSkop2 microscope (Dublin, CA) interfaced
with OpenLab imaging software (Boston, MA).
Western Blot Analysis
Brain tissue was homogenized in whole cell lysis buffer and
protein concentrations were measured using a Bradford Assay
(Bio-Rad, Hercules, CA). Samples were prepared and run on
SDS-PAGE gels (10 % for SOD3, 12 % for SOD2, and 15 %
for SOD1). Nitrocellulose membranes were blocked in 5 %
nonfat milk in TBS+0.1 % Tween (TBST) for 1 h at 25 °C
and probed with the following primary antibodies overnight at
4 °C: mouse α-SOD3 (1:500; Novus Biologicals) [47], rabbit
α-SOD1 (1:500; Abcam, San Francisco, CA) [49], or rabbit
α-SOD2 (1:500; Novus Biologicals) [50]. Membranes were
then probed with AlexaFluor® 488 goat α-rabbit IgG (1:250)
or AlexaFluor® 488 goat α-mouse IgG1 (1:250) for 1 h at
25 °C and visualized using a Typhoon 9410 Imager (GE
Healthcare Life Sciences, Marlborough, MA). Membranes
were also probed with mouse α-β-actin (1:5000; Novus
Biologicals) [51] antibodies. All protein bands of interest were
normalized to β-actin bands to act as a loading control.
SOD Inhibition Assay
Prior to assay, brain tissue samples were diluted in an equal
volume of dilution buffer to lower detergent concentrations.
Percent inhibition of SOD activity was measured according to
the manufacturer’s protocol (K-Assay, Seattle, WA).
Absorbance was measured at 450 nm using a μQuant micro-
plate spectrophotometer (BioTek, Winooski, VT) and KC
Junior software (BioTek). The following equation was used
to calculate % inhibition:
ABlank 1−ABlank 3ð Þ− ASample−ABlank 2
  
= ABlank 1−ABlank 3ð Þ  100%
Average % inhibition rates for each set of sample dilutions
were graphed using the nonlinear regression function. The
slope of the linear portion of each standard curve was used
to calculate the IC50 for each sample. The IC50 and protein
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concentrations of samples were used to calculate units of SOD
activity per milligram protein lysate (U/mg).
Cortical Neuronal Cultures
Rat primary cortical neurons were isolated as previously de-
scribed [52]. Cells were counted using the Trypan Blue exclu-
sion method and seeded at a density of 800,000 cells/well into
12-well plates coated with 0.1 mg/ml poly-L-lysine solution.
Neurobasal complete media containing B-27 supplement and
1.25 mM glutamine (Life Technologies) was changed 24 h
after seeding and subsequent media changes occurred on a
weekly basis. Neurons were used between 7 and 15 days in
vitro.
In Vitro Ischemia
Oxygen glucose deprivation (OGD) was performed as previ-
ously described to induce in vitro ischemia [46]. Cells were
given a fresh media change: 1 ml Dulbecco’s modified
Eagle’s medium (DMEM) with 4.5 g/l D-glucose and sodium
pyruvate per well for control cells and 1 ml DMEMwithout D-
glucose or sodium pyruvate for cells subjected to OGD.
Neurons were treated with either 50, 200, or 1000 ng/ml LIF.
Sterile filtered PBS was used as a vehicle control for LIF. In
another experiment, neurons were treated with PBS or 200 ng/
ml LIF in the presence or absence of 10 μM Insolution™ Akt
Inhibitor IV (EMD Millipore). This inhibitor blocks the ATP
binding site of a kinase located upstream of Akt and down-
stream of PI3K. DMSO (0.1 %) was used as vehicle control
for Akt Inhibitor IV. Following treatment with LIF and Akt
Inhibitor IV, neurons were placed in an airtight chamber. This
chamber was flushed with a gas mixture containing 94 % N2,
5 % CO2, and 1 % O2 (Airgas, Tampa, FL) for 15 min prior to
sealing the chamber for 24 h. Following the 24-h incubation,
cells were removed from the chamber and supernatants were
collected to measure the release of lactate dehydrogenase
(LDH). Cells were washed twice with PBS, pelleted via centri-
fugation, and snap-frozen. Pellets were stored at −80 °C for
further biochemical analyses.
LDH Assay
Neuronal death was quantified by measuring the release of
LDH as previously described [46] using a colorimetric assay
kit (Takara Biosciences, Madison, WI). Cell supernatant sam-
ples were diluted 1:4 in fresh medium prior to assay to avoid
obtaining absorbance readings beyond the linear threshold.
Absorbance was read at 490 nm using a μQuant microplate
spectrophotometer (BioTek) and KC Junior software
(BioTek). To quantify approximate levels of neuronal death,
a standard curve was created as previously described [46] by
lysing known quantities of neurons with 2 % Triton X-100
and measuring LDH release.
Gene Silencing
Silencing the expression of SOD3 in cortical neurons was
achieved via transfection with small interfering RNA (siRNA).
This procedure was performed according to manufacturer’s pro-
tocol using a Nuclefector™ 2b Device and the Amaxa™ Basic
Nucleofector™ Kit for primary mammalian neurons (Lonza,
Allendale, NJ). Scrambled (Control-A) and siRNA sequences
directed against the rat SOD3 gene were purchased from Santa
Cruz Biotechnology. Freshly isolated cortical neurons were
transfected with either scrambled or SOD3 siRNA using proto-
col G-013. Cells were removed from cuvettes and seeded into
12-well plates containing pre-equilibratedDMEMcompleteme-
dium. Media was changed to Neurobasal Complete 24 h after
seeding. Suppression of SOD3 expression was confirmed using
quantitative reverse-transcriptase PCR (qRT-PCR).
Two-Step qRT-PCR
Two-step qRT-PCR was performed as previously described
with minor modifications [28]. AffinityScript® Master Mixes
for reverse-transcriptase and qPCR reactions were obtained
from Agilent Technologies (Santa Clara, CA). Synthesis of
complementary DNA (cDNA) was performed per manufac-
turer’s instructions in a Mastercycler Gradient thermal cycler
(Eppendorf, Hauppauge, NY). Reaction components were at
25 °C for 5 min to allow primers to anneal, 42 °C for 30 min
to allow cDNA synthesis, and 95 °C for 5 min to quench the
reaction. The concentration and quality of newly synthesized
cDNA was determined using a NanoDrop ND-1000 spectro-
photometer (Thermo-Fisher Scientific, Waltham, MA). Primer
sequences for rat SOD3 and GAPDH genes were obtained
from Qiagen (Valencia, CA). The qPCR reaction was per-
formed according to manufacturer’s instructions using the
Chromo4 DNA Engine thermal cycler and Opticon™ 3.1
Software (Bio-Rad) with the following steps: 15 min at 95 °C
to heat the reaction mixture, 30 s at 95 °C to denature strands,
30 s at 55 °C to allow primers to anneal, and 30 s at 72 °C for
strand elongation. This denaturing–annealing–elongation cycle
was repeated 40 times. Following the qPCR reaction, melt
temperature curve analysis was performed to detect the pres-
ence of primer–dimers in the reaction mixture. Cycle threshold
values were determined by setting the threshold to a value
where all samples were in the amplification phase.
Data Analysis
All DAB immunohistochemical images were uniformly
sharpened and converted to black and white using Jasc Paint
Shop Pro 9 (Eden Prairie, MN). Optical density measurements
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for Western blot bands and histochemical staining was per-
formed using ImageJ 1.49 (NIH, Bethesda, MD). All statisti-
cal tests were performed using GraphPad Prism 4.0 (La Jolla,
CA) software and all data are expressed as the mean±SEM. A
Pearson-D’Agostino test was used to determine normality
among data sets. Unless stated otherwise, experiments were
analyzed via a one-way ANOVA followed by Fisher’s
protected least significant difference post hoc test. Data with
significantly different variances between treatment groups or a
non-Gaussian distribution was analyzed via a Kruskal–Wallis
H test. Mann–Whitney U tests were used to determine signif-
icance between pairs and a Bonferroni correction was applied
to the P value based on the number of individual comparisons
made. Statistical significance was determined using an alpha
value set at P=0.05. All P values reported are one-tailed.
Results
LIF Increases Total SOD Activity and SOD3 Expression
72 h Post-MCAO
Total SOD activity was measured in brain lysates from rats
euthanized 24, 48, or 72 h afterMCAOor sham surgery.Mean
SOD activities were normalized to the mean activity in sam-
ples from 72 h sham-operated rats. Ipsilateral tissue samples
from all MCAO rats demonstrated a time-dependent increase
in SOD activity from 24 to 72 h, while activities in contralat-
eral samples remained stable throughout this period. SOD
activities were significantly altered among treatment groups
at 72 h post-MCAO (H (3) =13.29; P=0.004). SOD activity
was significantly higher in LIF-treated ipsilateral tissue com-
pared to PBS-treated ipsilateral tissue (U=1.00; P=0.0237).
In addition, there was a trend towards increased SOD activity
in the PBS and LIF ipsilateral samples compared to their con-
tralateral counterparts.
Western blotting was used to determine protein expression
of SOD1, SOD2, and SOD3 in brain tissue from rats eutha-
nized 72 h post-MCAO. At 72 h post-MCAO, SOD1was only
significantly induced in contralateral tissue from LIF-treated
rats (P=0.0051, F4,10 = 7.321). Contralateral SOD1 expres-
sion from LIF-treated rats was significantly higher than that
of ipsilateral tissue from PBS-injected rats (P=0.0026) and
ipsilateral tissue from the same treatment group (P=0.0004;
Fig. 1b). There were no significant differences in SOD2 ex-
pression between tissue samples at this time point (H
(4) = 8.400; P=0.0780), but there was a trend towards de-
creased SOD2 expression in ipsilateral tissue from LIF-
treated rats compared to other samples (Fig. 1c). SOD3 ex-
pression was significantly higher in ipsilateral tissue from
LIF-treated rats (P=0.0021, F4,10=9.271) compared to ipsi-
lateral tissue from PBS-treated rats (P=0.0111) and sham-
treated rats (P=0.008; Fig. 1d). SOD3 expression remained
relatively constant between the sham and contralateral
samples.
Immunohistochemistry was used to visualize SOD3 ex-
pression within the intact cortical tissue. Representative im-
ages show several SOD3-positive cells in the ipsilateral cortex
of PBS-treated rats. However, these SOD3-positive cells ap-
peared dysmorphic (black arrows) and many cells were
surrounded by noticeable tissue lesions. By contrast, stained
ipsilateral tissue from LIF-treated rats revealed SOD3-positive
cells that retained a common triangular morphology compared
to those found in PBS-treated rats. These cells were arranged
in an orderly fashion and less tissue damage was observed in
the LIF-treated rat brains. Contralateral cortical staining from
both treatment groups did not reveal noticeable SOD3 staining
(Fig. 2a). Quantitative analysis of cortical staining revealed
induction of SOD3 in the ipsilateral cortex following LIF
treatment (P< 0.0001, F3,15 = 24.38). Among PBS-treated
rats, elevated levels of SOD3 were observed in the ipsilateral
cortex compared to the contralateral cortex (P= 0.0111).
However, LIF treatment yielded a significantly higher SOD3
expression in the ipsilateral cortex compared to PBS treatment
(P=0.0048). Levels of SOD3 staining were normalized to
sham tissue to account for baseline SOD3 expression in the
ipsilateral cortex (Fig. 2b).
SOD3 Is Induced in Cortical Neurons Following LIF
Treatment
To determine whether LIF exerts positive neurotrophic effects
on cortical neurons, brain tissue sections and cultured neurons
were labeled with antibodies against LIFR and MAP2.
Staining revealed localization of LIFR in neurons of the cere-
bral cortex (Fig. 3a). Cultured cortical neurons also expressed
basal LIFR levels under physiological in vitro conditions
(Fig. 3b). Tissue sections from LIF-treated animals that were
euthanized 24 and 72 h post-MCAOwere double-labeled with
SOD3 and MAP2 antibodies. MAP2-positive neurons were
observed at 24 and 72 h after MCAO (Fig. 3c, d). Likewise,
SOD3-positive cells were also visualized at these time points
(Fig. 3e, f). DAPI was used to indicate the presence of cell
nuclei at both time points (Fig. 3g, h). Co-localization of
SOD3 and MAP2 was observed at 24 and 72 h after
MCAO, indicating the presence of SOD3-positive neurons
at both time points (Fig. 3i, j).
To determine whether this increase in neuronal SOD3 oc-
curred in conjunction with Akt activation, tissue sections from
LIF-treated rats euthanized at 24 and 72 h after MCAO were
double-labeled with antibodies against SOD3 and Akt phos-
phorylated on residue Ser473 (phospho-Akt). Several cells
stained positive for phospho-Akt at 24 and 72 h post-MCAO
(Fig. 4a, b). Likewise, SOD3-positive cells were also visual-
ized at both time points (Fig. 4c, d). Cell nuclei were labeled
using DAPI at 24 and 72 h post-MCAO (Fig. 4e, f). Cells
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staining positive for phospho-Akt and SOD3were observed at
24 and 72 h post-MCAO (Fig. 4g, h).
LIF Protects Neurons from In Vitro Ischemic Damage
This laboratory previously demonstrated that 200 ng/ml LIF
protects oligodendrocytes during OGD [40]. A similar con-
centration response experiment was performed to determine
whether this concentration of LIF confers neuroprotection
against in vitro ischemia. Subjecting neurons to 24 h OGD
and treating with LIF yielded a significant change in LDH
release (H (7) = 25.74; P = 0.0006) Treating cells with
200 ng/ml LIF significantly decreased LDH release compared
to PBS-treated neurons that were subjected to the same 24-h
OGD exposure (U=7.000; P=0.0256; Fig. 5a). To confirm
the results of the LDH assay, neuronal cultures were subjected
to the same conditions and treatments but were subsequently
labeled with antibodies generated against activated caspase-3.
Representative images show levels of active caspase-3 in neu-
rons following 24 h normoxia, 24 h OGD+PBS, or 24 h
OGD+200 ng/ml LIF (Fig. 5b). Immunohistochemical anal-
ysis revealed significant changes in caspase-3 activation trig-
gered by OGD exposure and LIF treatment (P= 0.0003,
F2,9 = 23.57). Caspase-3 immunoreactivity was significantly
Fig. 1 LIF increases SOD activity and SOD3 Expression. a Total SOD
activity was measured in brain lysates from PBS- and LIF-treated rats
euthanized 24, 48, or 72 h post-MCAO. LIF ipsilateral samples had
significantly higher SOD activity compared to PBS-treated ipsilateral
samples at 72 h post-MCAO (*P < 0.05). Mean activities were
normalized to SOD activity in brains from sham rats. n ≥ 5 samples per
group. b At 72 h after MCAO, SOD1 expression was significantly
increased in contralateral tissue of LIF-treated rats, compared to
ipsilateral tissue from PBS-treated rats (*P< 0.01) and ipsilateral tissue
from the same treatment group (#P< 0.001). SOD1 bands were observed
at approximately 18 kDa. c There was a trend towards decreased SOD2
expression in the ipsilateral samples from the LIF group; however, this
decrease was not significant. SOD2 bands were observed at
approximately 25 kDa. d Ipsilateral samples from LIF-treated rats
showed a corresponding increase in SOD3 expression compared to PBS
(*P < 0.05) and sham (#P < 0.01) ipsilateral samples. Three bands
corresponding to SOD3 were observed in all samples at approximately
50, 80, and 130 kDa. n = 3 samples per group. Ips ipsilateral, Contra
contralateral
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higher after 24 h OGD+PBS compared to 24 h normoxia
(P=0.0003) while LIF treatment reduced caspase-3 activation
during OGD compared to PBS treatment (P=0.0128; Fig. 5c).
Neuroprotective Effects of LIFAre Dependent upon Akt
Activity
To determine whether the protective effects of LIF are depen-
dent upon Akt activity, neurons were treated with PBS+0.1%
DMSO, 200 ng/ml LIF+0.1 % DMSO, PBS+10 μM Akt
Inhibitor IV, or 200 ng/ml LIF+10 μMAkt Inhibitor IV prior
to OGD. LIF and Akt IV treatment both exerted significant
effects on LDH release following 4 h OGD (H (3) =17.55;
P=0.0005). Treatment with 200 ng LIF significantly reduced
LDH release compared to PBS (U=15.00; P=0.0012). Co-
incubating cells with 10 μMAkt Inhibitor IVand LIF yielded
significantly higher levels of LDH compared to neurons
Fig. 2 LIF upregulates SOD3 in the ipsilateral cortex. a Representative
images of cortical tissue from PBS rats show higher levels of SOD3
staining compared to contralateral tissue from the same group.
However, these cells appeared dysmorphic and unhealthy. LIF
treatment increased SOD3 expression in the ipsilateral cerebral cortex
while visibly reducing damage to SOD3-positive cells and surrounding
tissue. b After normalizing to sham SOD3 levels, immunohistochemical
quantification revealed significantly higher levels of staining in ipsilateral
tissue compared to contralateral tissue in PBS-treated rats (*P< 0.05).
LIF treatment further raised SOD3 in the ipsilateral tissue compared to
PBS (#P < 0.01). n = 5 per treatment group. Scale bars = 50 μm. Ips
ipsilateral, Contra contralateral
Fig. 3 Cortical neurons express SOD3 after LIF treatment. aCo-labeling
tissue withMAP2 (green) and LIFR (red) antibodies revealed localization
of LIFR in the neuronal somata. LIFR was concentrated primarily in the
cytoplasm and perinuclear region. b Cultures of cortical neurons also
showed LIFR staining in the cell bodies. Following LIF treatment,
neurons stained positive for MAP2 at c 24 h and d 72 h post-MCAO.
SOD3 immunoreactivity was observed in the brains of LIF-treated rats at
e 24 and f 72 h afterMCAO. g, hDAPI was used to stain for cell nuclei. i,
j Co-localization with the neuronal marker MAP2 indicates that SOD3 is
expressed by neurons in vivo following LIF treatment. Arrows indicate
representative cells. Scale bars= 20 μm
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treated with LIF alone (U=19.00; P=0.0024; Fig. 6a). To
determine whether this decrease in neuronal death correlated
with higher expression of SOD3 in vitro, representative cov-
erslips subjected to 24 h normoxia or 24 h OGD with
DMSO+PBS, DMSO+LIF, Akt Inhibitor IV+PBS, or Akt
Inhibitor IV+LIF treatment were stained with antibodies di-
rected against phospho-Akt or SOD3. Neurons incubated un-
der normoxia revealed low basal levels of phospho-Akt and
SOD3 (Fig. 6(B, C)). Cells treated with DMSO+PBS follow-
ed by 24 h OGD yielded higher levels of phospho-Akt and
SOD3 compared to normoxic cells (Fig. 6(D, E)). However,
neurons that were treated with DMSO+LIF prior to OGD
showed high levels of phospho-Akt and SOD3 while
returning to the healthy morphology seen in normoxic cells
(Fig. 6(F, G)). Treatment with Akt Inhibitor IV+PBS prior to
OGD decreased phospho-Akt compared to the neurons treated
with DMSO+PBS (Fig. 6(H)), but SOD3 levels did not
change (Fig. 6(I)). Co-incubation with LIF and Akt Inhibitor
IV lowered phospho-Akt and SOD3 staining compared to
neurons treated with DMSO+LIF (Fig. 6(J, K)).
Neuroprotection Against OGD by LIF Is Dependent
upon Increased SOD3 Expression
Transfection with siRNA and treatment with LIF prior to 24 h
OGD significantly altered levels of SOD3 messenger RNA
(mRNA) in primary cortical neurons (P < 0.0001, F3,
17=17.51). LIF significantly increased SOD3mRNA compared
to PBS treatment in cells transfected with scrambled siRNA
(P=0.0023). Transfection with SOD3 siRNA significantly
downregulated the expression of SOD3 compared to scrambled
siRNA (P=0.0165). Transfection with SOD3 siRNA prior to
LIF treatment significantly decreased SOD3 expression com-
pared to scrambled siRNA+PBS cells (P = 0.0212) and
siRNA+LIF cells (P=0.0005; Fig. 7a). LIF and siRNA treat-
ment yielded an overall trend towards altered LDH release fol-
lowing 24 h OGD (P=0.1701, F3,8=2.165). However, LIF
treatment significantly reduced LDH release among neurons
transfected with scrambled siRNA (P<0.05; Bonferroni meth-
od; Fig. 7b). Representative images show levels of active
caspase-3 among treatment groups (Fig. 7c). Treatment with
LIF and SOD3 siRNA significantly altered caspase-3 activation
following OGD (P=0.0002, F3,13 =14.50). LIF significantly
reduced caspase-3 activation following OGD compared to
PBS treatment among scrambled siRNA-transfected cells
(P=0.0104). SOD3 siRNA+PBS treatment prior to OGD sig-
nificantly increased activation of caspase-3 compared to scram-
bled siRNA+PBS treatment (P=0.0003). LIF significantly
lowered caspase-3 activation compared to PBS among SOD3
siRNA-transfected cells (P=0.0214). However, SOD3 knock-
down prevented LIF from reducing caspase-3 activation com-
pared to scrambled siRNA+PBS cells (Fig. 7d).
Discussion
SOD3, unlike SOD1 and SOD2, is not highly expressed by
neural cells under normal physiological conditions [23, 53].
Nonetheless, several distinct neuronal populations will up-
regulate SOD3 following FCI, including cortical and striatal
neurons [54]. These data demonstrate that LIF treatment
further increases SOD3 in neurons following ischemic in-
jury. At 72 h post-MCAO, antibodies against SOD3 detect-
ed three Western blot bands corresponding to the monomer
(40 kDa), dimer (80 kDa), and tetramer (140 kDa) of
SOD3. Wild-type SOD3 is expressed as a dimer in rats;
compared to the tetrameric human and murine isoforms, a
single-point mutation of the Asp residue at position 24 may
yield a tetrameric SOD3 isoform [55]. This mutant isoform
Fig. 4 SOD3 co-localizes with phospho-Akt (Ser473). Levels of
phospho-Akt (Ser473) increased from a 24 h to b 72 h after MCAO,
which corresponded with increased SOD3 staining over this same time
period (c, d). DAPI was used to stain for cell nuclei (e, f). The number of
cells staining positive for phospho-Akt (Ser473) and SOD3 increased
from g 24 h to h 72 h post-MCAO. Arrows indicate representative
cells. Scale bars= 20 μm. P-Akt phospho-Akt (Ser473)
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may correspond to the smaller, high molecular weight band
at 140 kDa. These findings were further confirmed by mea-
suring SOD3 immunoreactivity in the cerebral cortex.
Immunohistochemical analysis revealed higher levels of
SOD3 in the ipsilateral tissue of sham rats compared to
the ipsilateral cortex of PBS-treated rats. The higher level
of staining is most likely due to the higher number of
viable neural cells in the cortex after sham operation com-
pared to MCAO. Cells expressing SOD3 after LIF treat-
ment had a morphology resembling pyramidal neurons, and
double-labeling tissue with MAP2 and SOD3 antibodies
confirmed neuronal localization of SOD3.
Western blotting and histochemical analysis revealed that
SOD3 was upregulated in the ipsilateral, but not contralateral
hemisphere at 72 h post-MCAO. The absence of LIF-
mediated cellular protection under normoxia reflects previous
findings with cultured oligodendrocytes [40]. Decreased LDH
release from cultured oligodendrocytes following LIF treat-
ment was not observed under normoxia, but LIF significantly
reduced LDH release during OGD [40]. Although LIF is
transported into the brain via an ATP-dependent carrier [56],
Pan et al. demonstrated that LIF transport increases following
neuronal injury [57]. Breakdown of the BBB following per-
manent FCI [58] could allow LIF to reach the ipsilateral
Fig. 5 LIF treatment protects
neurons in vitro against OGD. a
Following 24 h OGD, 200 ng/ml
LIF significantly reduced cell
death compared to PBS treatment
(#P< 0.05). n ≥ 3 per treatment
group. b Images show neurons
stained with α-active caspase-3
antibodies after 24 h normoxia,
24 h OGD+PBS, and 24 h
OGD+200 ng/ml LIF. Arrows
identify representative cells. c
Neurons treated with PBS prior to
OGD had significantly higher
levels of active caspase-3
(*P< 0.001) compared to the
24 h normoxia group. LIF
treatment prior to 24 h OGD
decreased caspase-3 activation
compared to PBS (#P< 0.05).
Arrows identify representative
cells. n = 4 per treatment group.
Scale bar= 50 μm. Norm 24 h
normoxia
616 Mol Neurobiol (2017) 54:608–622
hemisphere via paracellular transport. In addition, negative
feedback mechanisms that regulate PI3K/Akt signaling under
physiological conditions are compromised under FCI [59].
Finally, minimal levels of cellular death under normoxia
may account for the lack of significant LIF-mediated neuro-
protection under normoxic conditions. Despite the overall in-
crease in SOD activity, neither SOD1 nor SOD2 expression
was significantly altered from the ipsilateral tissue of PBS-
treated rats. The trend towards decreased SOD2 expression
in the ipsilateral hemisphere of LIF-treated rats is most likely
due to increased activation of Akt. Previous findings show
that Akt may downregulate SOD2 expression via inactivation
of the transcription factor FoxO3 [60–62]. Significantly
higher levels of SOD1 at 72 h post-MCAO were observed
after LIF treatment, but only in contralateral tissue. This find-
ing reflects studies where LIF treatment ameliorates the ALS-
like symptoms seen in G93Amice [38, 39]. AlthoughWestern
blotting did not show increased SOD1 in the ipsilateral tissue
of LIF-treated rats, ischemic conditions may cause SOD1 to
aggregate. These insoluble aggregates would not be detected
in the portion of lysates used for Western blot analysis [63].
The answer to the difference between the efficacies of LIF
under normoxia vs ischemia may lie in the regulation of
LIFR/gp130. Immunohistochemical detection of LIFR in neu-
rons incubated under normoxia showed that LIF could hypo-
thetically trigger protective signaling in the absence of ische-
mia. Moreover, oligodendrocytes express LIFR under basal
conditions [37]. Future studies may be needed to further ex-
plain how LIF signal transduction is regulated in neurons.
Several groups reported that the termination of LIF signaling
is facilitated via the phosphorylation of both receptor subunits
[64, 65]. Our immunohistochemical staining reveals high
levels of nuclear LIFR in the absence of LIF signaling.
Nuclear LIFR was previously seen under physiological con-
ditions in several cell types, including neurons of the dorsal
root ganglion. However, injury to the dorsal root ganglion
caused LIFR to translocate from the nucleus to the cytoplasm
[66, 67]. Endocytosis of LIFR and gp130 has been previously
reported by multiple independent groups [68–70]. While the
Fig. 6 In vitro neuroprotection by LIF is dependent upon Akt activity. a
LIF treatment significantly lowered neuronal death during OGD
compared to PBS (*P< 0.001). b Akt IV reverses the neuroprotective
effect of LIF treatment alone (#P< 0.01). n = 12 per treatment group.
Representative images show B p-Akt and C SOD3 immunoreactivity in
neurons under normoxia. DMSO+ PBS treatment before 24 h OGD
increased D p-Akt and E SOD3 levels compared to 24 h normoxia. F
Phospho-Akt (Ser473) and G SOD3 levels were highest in cells treated
with DMSO+LIF before OGD. Addition of Akt IV+ PBS prior to OGD
causedH a minimal decrease in phospho-Akt (Ser473) and I no change to
SOD3 levels compared to the DMSO+PBS group. Co-incubation with
Akt Inhibitor IV +LIF prior to OGD prevented the LIF-induced increase
in J phospho-Akt (Ser473) and K SOD3 expression. Arrows identify
representative cells. P-Akt phospho-Akt (Ser473), Akt IV Akt Inhibitor
IV. Scale bar = 25 μm
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internalization of LIFR may precede its degradation, it is also
possible that the majority of LIFR remains in the nucleus until
stimulation with LIF promotes its trafficking to the cell
membrane.
The increase in SOD3 mRNA and decrease in LDH
release/caspase-3 activation following LIF treatment indicates
that upregulation of SOD3 is responsible for LIF’s protective
effects against OGD. Furthermore, LIF-treated neurons that
were previously transfected with SOD3 siRNA showed no
significant difference in LDH release and caspase-3 activation
compared to PBS-treated neurons transfected with scrambled
siRNA. These results indicate that LIF primarily protects neu-
rons against ischemic oxidative damage via SOD3 upregula-
tion. LIF and siRNA treatment yielded a significant overall
change among treatment groups when caspase-3 activation
was measured, but not LDH. This discrepancy between these
results could be due to several factors. LDH release corre-
sponds to the rate of necrosis [71] while caspase-3 cleavage
corresponds to apoptosis. Previous research indicates that
neurons undergo both processes during FCI [72, 73].
Caspase-3 activation may be detected prior to LDH release,
indicating that staining will identify cells with intact mem-
branes that are beginning to undergo programmed death
[74]. Moreover, the larger increase in caspase-3 activation
may be due to the inhibitory effect of SOD3 and active Akt
on caspase-3-mediated apoptosis [61, 75].
Previous data from this lab indicated that injection of LIF
improved several outcomes including infarct size, white mat-
ter damage, and functional motor skills at 72 h after permanent
FCI. In vitro experiments using cultured oligodendrocytes and
Prdx4 antibodies confirmed that the ability of LIF to reduce
oxidative damage to white matter during stroke is primarily
dependent upon its upregulation of Prdx4 through PI3K/Akt
signaling [40]. Prdx4, not unlike SOD3, may be secreted into
the extracellular environment to scavenge ROS [76, 77]. By
neutralizing extracellular ROS, enzymes such as SOD3 and
Prdx4 may protect other cells in the parenchyma by
preventing further intracellular damage. LIF-mediated
Fig. 7 LIF increases cell survival by upregulating SOD3. aLIF treatment
prior to 24 h OGD increased SOD3 mRNA among neurons transfected
with scrambled siRNA (*P< 0.01). SOD3 siRNA treatment + PBS prior
to OGD significantly decreased SOD3 mRNA compared to scrambled
siRNA+PBS (#P< 0.05). SOD3 siRNA+LIF reduced SOD3 mRNA
compared to scrambled siRNA + LIF (^P < 0.001) and scrambled
siRNA + PBS. n ≥ 4 per treatment group. b LDH release was
significantly lower in scrambled siRNA-transfected cells treated with
LIF compared to their PBS-treated counterparts (*P< 0.05) while LIF
treatment did not reduce LDH release in SOD3 siRNA-transfected cells
compared to SOD3 siRNA+ PBS cells. n = 3 per treatment group. c
Representative cells show levels of active caspase-3 among treatment
groups. d Active caspase-3 immunoreactivity was significantly reduced
by LIF treatment in neurons transfected with scrambled siRNA compared
to Scr + PBS cells (*P< 0.05). Transfection with SOD3 siRNA+PBS
treatment significantly increased caspase-3 activation compared to
Scr + PBS treatment (#P < 0.001). SOD3 siRNA + LIF cells had
significantly lower levels of active caspase-3 compared to SOD3
siRNA + PBS cells (^P < 0.05), but not Scr + PBS cells. n ≥ 3 per
treatment group. Scr scrambled siRNA. Scale bar= 50 μm
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upregulation of SOD3 and Prdx4 in the brain may help regu-
late redox balance after FCI. Since hydrogen peroxide and
water are products of SOD-catalyzed reactions, higher
SOD3 expression could potentially lead to excess peroxida-
tion of cellular components. Peroxiredoxin family enzymes
catalyze the breakdown of hydrogen peroxide to water and
oxygen [78–80]. Therefore, increased Prdx4 expression fol-
lowing LIF treatment would prevent the buildup of hydrogen
peroxide generated from excess SOD activity.
Although results from in vitro experiments indicate that the
neuroprotective effects of LIF are attenuated following siRNA-
mediated knockdown of SOD3, this does not necessarily mean
that SOD3 upregulation is the only mechanism of in vivo neu-
roprotection. Unfortunately, there are no selective SOD3 inhib-
itors that could be administered following MCAO. Due to the
lack of tissue-specific knockout rats available, obtaining a
neuron-specific SOD3 knockout rat strain for these experiments
would be difficult. To demonstrate that induction of Prdx4 was
necessary for in vitro oligoprotection, this laboratory used neu-
tralizing antibodies to block Prdx4 activity prior to OGD [40]. It
is likely that the improvement in sensorimotor skills and smaller
infarct volume after LIF treatment may be attributed to protec-
tivemechanisms other than Prdx4 induction. This lab has shown
that LIF confers protection in multiple neural cell types during
ischemia. Moreover, systemic LIF administration may result in
additional protection that is independent of its effects on cell
survival. For instance, LIF plays a crucial role in the develop-
ment of regulatory T lymphocytes and alternatively activated
(M2) macrophages/microglia [81, 82]. As a result, LIF may
reduce neurodegeneration triggered by the release of inflamma-
tory splenocytes after stroke. Further investigation will be nec-
essary to determine whether its primary neuroprotective mech-
anism in vivo is dependent upon SOD3.
This laboratory previously measured infarct volume after
LIF treatment using Fluoro-Jade staining due to its ability to
specifically label dying neurons [40, 83]. Although a lower
number of viable neurons in the infarct and penumbra could
contribute to a significant reduction in the total area of Fluoro-
Jade-positive tissue, the improvement in motor skills among
LIF-treated rats indicated that LIF reduced neuronal degrada-
tion in addition to protecting oligodendrocytes in vivo [66].
Previous studies indicate that LIF mRNA levels are approxi-
mately 30 times higher in astrocytes 6 h after cortical brain
injury compared to pre-injury levels.Microglia were also found
to have elevated levels of LIF mRNA at this same time point
[41]. This upregulation of LIF transcript following injury to the
gray matter indicates that LIF may serve as an endogenous
protective factor against neuronal injury. However, the magni-
tude of damage observed after our model permanent FCI indi-
cates that endogenous LIF release is not sufficient to rescue
neurons in the penumbra. These data indicate that damage
may be reduced via exogenous supplementation of LIF follow-
ing injury.
Further studies will be needed to determine the mechanism
of LIF-mediated upregulation of SOD3 in neurons. Our group
and others have demonstrated that LIF controls the expression
of protective genes at the transcriptional level [40, 84].
Therefore, LIF may be activating transcription factors down-
stream of Akt. The reduced infarct size and improved motor
skills observed after LIF treatment in previous studies suggest
that it may exert pro-survival effects independent of antioxi-
dant enzymes [40]. Nevertheless, the ability to induce protec-
tive antioxidant enzymes makes LIF a promising treatment
that will protect neural cells against immediate and delayed
damage following ischemic stroke.
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